John Fesko Sells 707 Shares of Natera (NASDAQ:NTRA) Stock

March 12, 2026 by InsiderTrades.com

Key Points

Natera CEO Steven Leonard Chapman sold 5,623 shares on March 10 for $1,147,822.99 (avg $204.13), reducing his stake by about 3.47% to 156,607 shares.
The March sale is part of a larger pattern of recent insider disposals — including blocks of 85,299 and 71,932 shares in early February and January — which likely contributed to near‑term downward pressure on the stock.
Natera beat the quarter: reported EPS $0.35 (vs. -$0.46 est.) and revenue $665.5M (vs. $600.7M est.), but remains unprofitable on margin metrics; shares trade near $194 with a consensus analyst target around $253.47.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 707 shares of the company's stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $204.13, for a total transaction of $144,319.91. Following the transaction, the insider owned 189,199 shares in the company, valued at approximately $38,621,191.87. The trade was a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

3 Under-the-Radar Healthcare Companies

John Fesko also recently made the following trade(s):

On Tuesday, February 3rd, John Fesko sold 3,594 shares of Natera stock. The shares were sold at an average price of $231.02, for a total transaction of $830,285.88.
On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $220,548.48.
On Tuesday, January 27th, John Fesko sold 784 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $188,575.52.
On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $79,665.00.
On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $4,179,780.44.

Natera Stock Down 0.9%

NTRA stock traded down $1.79 during mid-day trading on Thursday, reaching $194.82. 101,539 shares of the company traded hands, compared to its average volume of 1,163,046. The firm's 50 day moving average price is $221.32 and its 200 day moving average price is $206.07. The stock has a market cap of $27.61 billion, a price-to-earnings ratio of -127.64 and a beta of 1.65. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same period in the prior year, the business posted ($0.41) earnings per share. On average, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Citigroup began coverage on Natera in a research note on Wednesday, January 7th. They set a "buy" rating and a $300.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating on shares of Natera in a report on Monday, January 12th. Wells Fargo & Company raised their price target on shares of Natera from $205.00 to $215.00 and gave the company an "equal weight" rating in a research report on Friday, February 27th. Stephens boosted their price target on shares of Natera from $197.00 to $235.00 and gave the stock an "overweight" rating in a report on Thursday, November 13th. Finally, UBS Group boosted their price target on shares of Natera from $218.00 to $280.00 and gave the stock a "buy" rating in a report on Tuesday, November 18th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and an average price target of $253.47.

Check Out Our Latest Report on Natera

Hedge Funds Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. Horizon Investments LLC raised its holdings in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock valued at $56,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC lifted its position in shares of Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company's stock worth $62,000 after acquiring an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its holdings in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company's stock worth $353,000 after acquiring an additional 46 shares during the period. Siemens Fonds Invest GmbH boosted its holdings in shares of Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock worth $290,000 after acquiring an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH grew its position in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock valued at $515,000 after purchasing an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

Positive Sentiment: MyOme announced the Zenith™ portfolio with Natera and launched long‑read methylation analysis at ACMG 2026 — a commercial/technology collaboration that could broaden Natera's rare‑disease whole‑genome and epigenetic testing capabilities and help expand addressable market and clinical utility over time. MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
Neutral Sentiment: Natera presented at the Leerink Global Healthcare Conference (transcript available). Management commentary in the presentation could provide useful color on product launches, adoption trends, and margin/reimbursement dynamics — read for guidance but the transcript itself is informational rather than catalytic. Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Negative Sentiment: Significant insider selling disclosed: CEO Steven Leonard Chapman sold 5,623 shares (~$1.15M at ~$204.13) and reduced his stake ~3.47%; other insiders (CFO Michael Brophy, John Fesko, Solomon Moshkevich) also sold smaller positions. Multiple insider sales on the same date increase perceived near‑term selling risk and likely explain part of downward pressure on the shares. SEC Form 4 — CEO Sale

About Natera

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.